Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 476.37% from the company’s current price.
Separately, StockNews.com initiated coverage on shares of Can-Fite BioPharma in a research report on Saturday. They set a “sell” rating for the company.
Get Our Latest Analysis on Can-Fite BioPharma
Can-Fite BioPharma Stock Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 58.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the quarter. Rhumbline Advisers owned approximately 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors and hedge funds.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Recommended Stories
- Five stocks we like better than Can-Fite BioPharma
- What Are Dividend Challengers?
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 Warren Buffett Stocks to Buy Now
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
- The How and Why of Investing in Gold Stocks
- Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.